Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: An emulated trial study
In comparison, 7,293 individuals (8.0%) with an estimated HbA1c advantage on GLP1-RA showed a 16 mmol/mol drop in HbA1c, whereas SGLT2i recipients had a nine mmol/mol decrease in HbA1c
The SURMOUNT trials reported average weight reductions of approximately 20% or more in certain study populations using tirzepatide 15mg weekly
The medication binds to specific receptors in your pancreas, brain, and digestive tract
As GLP-1 costs rise, utilization increases, and new formulations and indications enter the market, employers are also making key decisions against a backdrop of broader health plan cost pressures and worsening population health
